CUCCI, Marie Angele
CUCCI, Marie Angele
SCIENZE CLINICHE E BIOLOGICHE
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism
2020-01-01 Cucci M.A.; Grattarola M.; Dianzani C.; Damia G.; Ricci F.; Roetto A.; Trotta F.; Barrera G.; Pizzimenti S.
Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression
2019-01-01 Daga, Martina; Pizzimenti, Stefania*; Dianzani, Chiara; Cucci, Marie Angele; Cavalli, Roberta; Grattarola, Margherita; Ferrara, Benedetta; Scariot, Valentina; Trotta, Francesco; Barrera, Giuseppina
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
2016-01-01 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy
2001-01-01 G.L. ISOARDO; B. FERRERO; P. BARBERO; A. CUCCI; A. OGGERO; A. PIPIERI; A. RICCI; E. VERDUN; B. BERGAMASCO; L. DURELLI
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD).
2003-01-01 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
2005-01-01 E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a.
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP
Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells
2020-01-01 Ambrosio L.; Argenziano M.; Cucci M.A.; Grattarola M.; de Graaf I.A.M.; Dianzani C.; Barrera G.; Nieves J.S.; Gomez R.; Cavalli R.; Pizzimenti S.
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients.
2003-01-01 A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI
Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role
2021-01-01 Barrera G.; Cucci M.A.; Grattarola M.; Dianzani C.; Muzio G.; Pizzimenti S.
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients.
2003-01-01 M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
2004-01-01 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism | 2020 | Cucci M.A.; Grattarola M.; Dianzani C.; Damia G.; Ricci F.; Roetto A.; Trotta F.; Barrera G.; Pizzimenti S. | |
| Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression | 2019 | Daga, Martina; Pizzimenti, Stefania*; Dianzani, Chiara; Cucci, Marie Angele; Cavalli, Roberta; Grattarola, Margherita; Ferrara, Benedetta; Scariot, Valentina; Trotta, Francesco; Barrera, Giuseppina | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months | 2016 | De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy | 2001 | G.L. ISOARDO; B. FERRERO; P. BARBERO; A. CUCCI; A. OGGERO; A. PIPIERI; A. RICCI; E. VERDUN; B. BERGAMASCO; L. DURELLI | |
| Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation | 2005 | A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP | |
| Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). | 2003 | M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a | 2005 | E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP | |
| Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Carbosilane dendrimers loaded with sirna targeting nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells | 2020 | Ambrosio L.; Argenziano M.; Cucci M.A.; Grattarola M.; de Graaf I.A.M.; Dianzani C.; Barrera G.; Nieves J.S.; Gomez R.; Cavalli R.; Pizzimenti S. | |
| Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. | 2003 | A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
| Control of oxidative stress in cancer chemoresistance: spotlight on Nrf2 role | 2021 | Barrera G.; Cucci M.A.; Grattarola M.; Dianzani C.; Muzio G.; Pizzimenti S. | |
| Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. | 2003 | M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI | |
| Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial | 2004 | P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP |